Insmed CEO William Lewis sells 1.79 million in stock - Investing.com
| INSM Stock | USD 70.44 1.03 1.48% |
About 52% of Insmed's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Insmed Inc suggests that some traders are interested. Insmed's investing sentiment overview a quick insight into current market opportunities from investing in Insmed Inc. Many technical investors use Insmed Inc stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Insmed |
Insmed CEO William Lewis sells 1.79 million in stock Investing.com
Read at news.google.com
 |
Insmed Fundamental Analysis
We analyze Insmed's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Insmed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Insmed based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Insmed is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Insmed Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Insmed stock to make a market-neutral strategy. Peer analysis of Insmed could also be used in its relative valuation, which is a method of valuing Insmed by comparing valuation metrics with similar companies.
Peers
Insmed Related Equities
| AKRO | Akero Therapeutics | 3.31 | ||||
| DAWN | Day One | 2.65 | ||||
| FENC | Fennec Pharmaceuticals | 2.57 | ||||
| RNA | Avidity Biosciences | 2.48 | ||||
| SWTX | SpringWorks Therapeutics | 2.33 | ||||
| RVMD | Revolution Medicines | 1.78 | ||||
| RARE | Ultragenyx | 1.73 | ||||
| BPMC | Blueprint Medicines | 1.36 | ||||
| HRMY | Harmony Biosciences | 1.15 | ||||
| BGNE | BeiGene | 1.02 | ||||
| KROS | Keros Therapeutics | 0.65 | ||||
| APLS | Apellis Pharmaceuticals | 0.21 | ||||
| JANX | Janux Therapeutics | 0.14 | ||||
| EWTX | Edgewise Therapeutics | 0.06 | ||||
| HALO | Halozyme Therapeutics | 0.76 | ||||
| ASND | Ascendis Pharma | 0.99 | ||||
| AGIO | Agios Pharm | 1.09 |
Check out Insmed Hype Analysis, Insmed Correlation and Insmed Performance. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.